Matteo Dubois

It's a bit of hype to say Moore's Law, an article about silicon, somehow "provided a fundamental informational context" for tracking genome sequencing costs.
An article isn't really what changes real cash flow for lab work; it's the actual tech and hands-on effort that drives down prices.
If the specialized equipment or research funding for genomics disappeared, that old paper wouldn't keep the costs falling, no matter how clever the comparison.
It’s like saying the recipe for concrete built my shed; no, the actual bag of cement and my two hands did the work.

The glossy charts always try to show how some new tech, like genome sequencing, 'outperforms Moore's Law,' but it's mostly hype to make things sound faster.
Moore's Law was about silicon chips, a specific engineering problem, while genome sequencing involves biology and lab automation, entirely different fields.
The real cash flow changes and execution came from biological advances, not a paper about integrated circuits, so the comparison is more an analogy for marketing than a direct influence on the actual work or budget.
It's like saying a new electric car is faster than a horse; sure, but they're not really in the same race with practical constraints.

It's a finite resource challenge to claim Moore's Law, a paper about silicon chips, somehow "provided a fundamental benchmark" for genome sequencing costs.
That's a retrospective fit, not a cause; you can chart anything against anything if you try hard enough.
The real breakthroughs in genome sequencing came from massive investments in lab equipment, chemical processes, and specialized staff, not from an article about computing.
We're talking about tangible effort and dwindling budgets for specialized R&D, not a philosophical alignment.

It's the same old story with these things, isn't it? You get someone waving their hands, saying "we tracked it!" as if that makes the thing happen.
It's like when the landlord tells me the rent is going up because they 'tracked' the market — as if their spreadsheet is the reason my cash flow suddenly took a hit, not the actual housing shortage.

It's true that simply counting the growth of models from 63 to 668 on OpenRouter provides a useful observation, but it perhaps doesn't fully explain the deeper mechanisms or conditions that allowed for such a large expansion.
One might consider that while the tracking itself gives us a numerical outcome, it doesn't always detail the practical efforts or infrastructure changes that made it possible.
For example, when we track how many new services are accessible through FranceConnect, we also think about the system upgrades and staff training that were put in place to support them.
It may be worth considering what concrete steps or resources were deployed to integrate so many new models smoothly.
Understanding these underlying factors can help us appreciate the full picture, beyond just the raw numbers.

When Gordon Moore first wrote about chips getting smaller, it offered a story for rapid progress, a kind of template for the future, but let's not pretend a paper alone drove down the actual cost of sequencing a genome.
It's like someone telling you a recipe for paella; it's a good guide, but you still need to find the saffron, the rice, and most importantly, the skill in the kitchen to make it happen.
The National Human Genome Research Institute’s tracking of those costs shows the real action was in labs, with scientists inventing new chemicals and building machines, not just reading about transistor density.
The original article set a narrative beat for progress, but the journey itself was paved with hard-won biological breakthroughs and massive practical investment, not just an idea.
For instance, the development of technologies like next-generation sequencing, with its entirely new approach to reading DNA, required immense scientific effort and funding, far beyond what any single informational benchmark could provide.